Mid Regional Natriuretic Peptide for Predicting Prognosis of Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy

  • Niranjan Reddy R Assistant Professor, Department of Cardiology, Sapthagiri institute of medical sciences and research Centre, Bangalore, India
  • Magesh B Assistant Professor, Department of Cardiology, Sapthagiri institute of medical sciences and research Centre, Bangalore, India https://orcid.org/0000-0003-4478-8824
Keywords: Heart failure, Hypertrophic cardiomyopathy, immunoassay


Background: Hypertrophic cardiomyopathy (HCM) is a genetic disorder of cardiac myocytes that is characterized by cardiac hypertrophy, cellular disarray and interstitial fibrosis. Mutation of MYH7 and MYBPC3 encoding proteins β-myosin heavy chain and myosin binding protein C, respectively, are the two most common genes involved, together accounting for about 50% of cases. The present study was conducted to evaluate the prognostic value of MR-proANP in patients with HCM. Subjects and Methods: The present study was conducted at Narayana Medical College & Hospital, Chintareddy Palem, Nellore, Andhra Pradesh from July 2016 to July 2017 on 46 patients of hypertrophic cardiomyopathy of both genders. Serum NT-proBNP was measured by a two-site electrochemiluminescence immunoassay on a Roche Diagnostics E170 analyser. Results: The mean systolic blood pressure was 124.8 mm Hg, diastolic blood pressure was 78 mm Hg, heart rate was 68 beats/minutes, NYHA 1(n=4), NYHA 2 (n=27), NYHA 3–4 (n=15) and atrial fibrillation was 12%. The mean MR-proANP was 106 pmol/L and NT-proBNP was 540 pg/mL at the start of the study. At the end of 12 months of follow up, 15 patients had a primary end point defined as heart failure hospitalisation (n=10), heart transplant (n=3) death(n=2). Both mean MR-proANP and NT-proBNP were strongly associated with the primary end points at the end of study period with values of 1010 pmol/L and 2545 pg/ml respectively. This showed a strong association with P <0.05. Conclusion: Authors found that MR-proANP is a valuable biomarker for the prediction of heart failure related events in patients with HCM.


Download data is not yet available.


Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242–255. Available from: https://dx.doi.org/10.1016/s0140-6736(12)60397-3.

Elliott PM, Anastasakis A, Borger MA. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;2014:2733–79. Available from: https://dx.doi.org/10.1093/eurheartj/ehu284.

Volpe M, Rubattu S, Burnett J. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35(7):419–425. Available from: https://dx.doi.org/10.1093/eurheartj/eht466.

Yang H, Woo A, Monakier D, Jamorski M, Fedwick K, Wigle ED, et al. Enlarged Left Atrial Volume in Hypertrophic Cardiomyopathy: A Marker for Disease Severity. J Am Soc Echocardiogr. 2005;18(10):1074–1082. Available from: https://dx.doi.org/10.1016/j.echo.2005.06.011.

Epstein FH, Levin ER, Gardner DG, Samson WK. Natriuretic Peptides. N Eng J Med. 1998;339(5):321–328. Available from: https://dx.doi.org/10.1056/nejm199807303390507.

Maisel AS, Krishnaswamy P, Nowak RM. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–168. Available from: https://dx.doi.org/10.1056/NEJMoa020233.

Isnard R, Pousset F, Chafirovskaïa O, Carayon A, Hulot JS, Thomas D, et al. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J. 2003;146(4):729–735. Available from: https://dx.doi.org/10.1016/s0002-8703(03)00365-x.

Bégué C, Mörner S, Brito D, Hengstenberg C, Cleland JGF, Arbustini E, et al. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart. 2019;106(3):196–202. Available from: https://dx.doi.org/10.1136/heartjnl-2019-314826.

Briguori C. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J. 2001;22(15):1328–1336. Available from: https://dx.doi.org/10.1053/euhj.2000.2535.

Geske JB, McKie PM, Ommen SR, Sorajja P. B-Type Natri- uretic Peptide and Survival in Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2013;61(24):2456–2460. Available from: https://dx.doi.org/10.1016/j.jacc.2013.04.004.

How to Cite
Niranjan Reddy R, & Magesh B. (2020). Mid Regional Natriuretic Peptide for Predicting Prognosis of Hypertrophic Cardiomyopathy. Academia Journal of Medicine, 3(1), 15-18. https://doi.org/10.47008/ajm.2020.3.1.4